HNCP

(redirected from Head and Neck Cancer Patient)
AcronymDefinition
HNCPHome Network Control Protocol
HNCPHead and Neck Cancer Patient
HNCPHead and Neck Cancer Program
References in periodicals archive ?
Distress in head and neck cancer patients results from a number of factors--physical, social, and emotional--and often involves communication difficulties.
No study has been done exclusively on the head and neck cancer patients. Therefore this study was planned with the rationale to look for the presence of psychiatric morbidity among the patients of head and neck tumors and assess the associated socio-demographic factors.
The HNC Living Foundation is a non-profit organization dedicated to providing assistance for head and neck cancer patients to improve their treatment, recovery, and quality of life.
Risk factor profiles of head and neck cancer patients of Andhra Pradesh, India.
Head and neck cancer patients have a high risk of developing a second primary head and neck malignancy.
He, however, added that the hospital sill had a long waiting list of non-urgent head and neck cancer patients as priority was given to more serious types of cancer cases.
Mr Paleri said: "Transoral Robotic Surgery will dramatically improve the way we treat head and neck cancer patients in future.
Now, researchers at Fox Chase Cancer Center find that poor psychosocial functioning is associated with VEGF, a signaling protein that not only stimulates tumor growth, but is also associated with shorter disease free survival in head and neck cancer patients,a private news channel reported.
Washington, May 11 (ANI): Researchers at the University of Michigan Comprehensive Cancer Center have found a novel way to reduce side effects in head and neck cancer patients receiving radiation treatments.
Analyses of predictive biomarkers defined subset populations of head and neck cancer patients that may achieve the most benefit from ADVEXIN treatment.
Irradiated head and neck cancer patients needing dental extractions may benefit from HBO.
has completed enrollment in its phase 2b clinical trial evaluating the efficacy, safety and tolerability of GC4419 as a treatment for reducing the incidence and duration of oral mucositis (OM) in head and neck cancer patients receiving chemoradiation therapy, the company said.